Stratifying tuberculosis (TB) disease into minimal, moderate or severe disease may allow treatment duration to be tailored to disease severity. Minimal poor adherence is associated with poor treatment outcomes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials
Trials Open Access 03 August 2021
-
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
Scientific Reports Open Access 25 May 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
World Health Organization. Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update (WHO, Geneva, 2017).
Savic, et al. Nat. Med. https://doi.org/10.1038/s41591-018-0224-2 (2018).
Gillespie, S. H. et al. N. Engl. J. Med. 371, 1577–1587 (2014).
Merle, C. S. et al. N. Engl. J. Med. 371, 1588–1598 (2014).
Jindani, A. et al. N. Engl. J. Med. 371, 1599–1608 (2014).
Kendall, E. A. et al. PLoS Med. 14, e1002202 (2017).
World Health Organization. Global Tuberculosis Report 2018 (WHO, Geneva, 2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Churchyard, G.J. A stratified approach to tuberculosis treatment. Nat Med 24, 1639–1641 (2018). https://doi.org/10.1038/s41591-018-0244-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-018-0244-y
This article is cited by
-
A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials
Trials (2021)
-
Recent Insights into the Structure and Function of Mycobacterial Membrane Proteins Facilitated by Cryo-EM
The Journal of Membrane Biology (2021)
-
RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response
Scientific Reports (2020)